Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
| Author | |
|---|---|
| Abstract |
:
Although induction studies of TPF in SCCHN have not improved outcomes compared to chemoradiotherapy alone, phase II studies of weekly carboplatin (CbP), paclitaxel and cetuximab (C225) have shown promising results. Nano-albumin-paclitaxel (nab-paclitaxel) based chemotherapy has demonstrated a higher response rate (RR) than solvent-based paclitaxel in squamous cell carcinoma of the lung with favorable toxicity. |
| Year of Publication |
:
2018
|
| Journal |
:
Oral oncology
|
| Volume |
:
84
|
| Number of Pages |
:
46-51
|
| ISSN Number |
:
1368-8375
|
| URL |
:
https://linkinghub.elsevier.com/retrieve/pii/S1368-8375(18)30246-X
|
| DOI |
:
10.1016/j.oraloncology.2018.06.028
|
| Short Title |
:
Oral Oncol
|
| Download citation |
